{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:24:24Z","timestamp":1773833064201,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.phrs.2013.12.003","type":"journal-article","created":{"date-parts":[[2013,12,22]],"date-time":"2013-12-22T09:02:00Z","timestamp":1387702920000},"page":"9-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9732-6039","authenticated-orcid":false,"given":"Ovidiu C.","family":"Baltatu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian E.","family":"Zaugg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pat","family":"Louie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana A.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2013.12.003_bib0005","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/11594140-000000000-00000","article-title":"The role of direct renin inhibition in clinical practice: focus on combination therapy","volume":"11","author":"Rashid","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.phrs.2013.12.003_bib0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000328702","article-title":"Endothelin antagonism and reversal of proteinuric renal disease in humans","volume":"172","author":"Barton","year":"2011","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.phrs.2013.12.003_bib0015","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.bbadis.2010.03.012","article-title":"Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans","volume":"1802","author":"Barton","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.phrs.2013.12.003_bib0020","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1517\/14656566.2010.485612","article-title":"Hypertensive nephropathy: prevention and treatment recommendations","volume":"11","author":"Hart","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.phrs.2013.12.003_bib0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2013.12.003_bib0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fphys.2012.00103","article-title":"Antidiuretic effects of the endothelin receptor antagonist avosentan","volume":"3","author":"Baltatu","year":"2012","journal-title":"Front Physiol"},{"key":"10.1016\/j.phrs.2013.12.003_bib0035","article-title":"Do endothelin receptor antagonists induce edema through an extravasation of fluids? Evidence from an experiment in bi-nephrectomized rats","volume":"26","author":"Maillard","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.phrs.2013.12.003_bib0040","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/clpt.2009.15","article-title":"Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects","volume":"85","author":"Smolander","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2013.12.003_bib0045","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1470320310392618","article-title":"Characterization of a stable, hypertensive rat model suitable for the consecutive evaluation of human renin inhibitors","volume":"12","author":"St-Jacques","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.phrs.2013.12.003_bib0050","series-title":"Hypertension 2008, joint congress 18th scientific meeting of the European society of hypertension and the 22nd scientific meeting of the international society of hypertension","article-title":"Efficacy and safety of the oral renin inhibitor spp635 once daily in patients with mild to moderate hypertension","author":"Hengelage","year":"2008"},{"key":"10.1016\/j.phrs.2013.12.003_bib0055","series-title":"Hypertension 2008, joint congress 18th scientific meeting of the European society of hypertension and the 22nd scientific meeting of the international society of hypertension","article-title":"Preclinical pharmacokinetic and pharmacodynamic characterization of spp635, a new direct renin inhibitor","author":"Zaugg","year":"2008"},{"key":"10.1016\/j.phrs.2013.12.003_bib0060","doi-asserted-by":"crossref","first-page":"R1122","DOI":"10.1152\/ajpregu.00703.2005","article-title":"Altered circadian rhythm reentrainment to light phase shifts in rats with low levels of brain angiotensinogen","volume":"290","author":"Campos","year":"2006","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.phrs.2013.12.003_bib0065","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1097\/01.ASN.0000033327.65390.CA","article-title":"Abolition of hypertension-induced end-organ damage by androgen receptor blockade in transgenic rats harboring the mouse ren-2 gene","volume":"13","author":"Baltatu","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2013.12.003_bib0070","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1161\/HYPERTENSIONAHA.108.117366","article-title":"Role of endothelin-1 in clinical hypertension: 20 years on","volume":"52","author":"Dhaun","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2013.12.003_bib0075","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.cellsig.2010.05.002","article-title":"Endothelin \u2013 biology and disease","volume":"22","author":"Khimji","year":"2010","journal-title":"Cell Signal"},{"key":"10.1016\/j.phrs.2013.12.003_bib0080","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000328697","article-title":"Endothelin in chronic proteinuric kidney disease","volume":"172","author":"Gagliardini","year":"2011","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.phrs.2013.12.003_bib0085","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/HYPERTENSIONAHA.110.167486","article-title":"Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease","volume":"57","author":"Dhaun","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2013.12.003_bib0090","first-page":"91","article-title":"Renin\u2013angiotensin system inhibitors in proteinuric chronic kidney disease","volume":"35","author":"Hirsch","year":"2009","journal-title":"Compr Ther"},{"key":"10.1016\/j.phrs.2013.12.003_bib0095","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1124\/jpet.111.178988","article-title":"Distinct actions of endothelin A-selective versus combined endothelin a\/b receptor antagonists in early diabetic kidney disease","volume":"338","author":"Saleh","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2013.12.003_bib0100","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2013.12.003_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00060.2009","article-title":"Regulation of blood pressure and salt homeostasis by endothelin","volume":"91","author":"Kohan","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.phrs.2013.12.003_bib0110","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.lfs.2012.03.026","article-title":"Endothelin and endothelin receptors in the renal and cardiovascular systems","volume":"91","author":"Vignon-Zellweger","year":"2012","journal-title":"Life Sci"},{"key":"10.1016\/j.phrs.2013.12.003_bib0115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s001090100210","article-title":"Tissue renin\u2013angiotensin systems: new insights from experimental animal models in hypertension research","volume":"79","author":"Bader","year":"2001","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.phrs.2013.12.003_bib0120","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00125-009-1540-3","article-title":"The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein e knockout mice","volume":"53","author":"Watson","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2013.12.003_bib0125","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1042\/cs0770129","article-title":"Binding sites for 125i-labelled endothelin-1 in the kidneys: differential distribution in rat, pig and man demonstrated by using quantitative autoradiography","volume":"77","author":"Davenport","year":"1989","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.phrs.2013.12.003_bib0130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/cs0910267","article-title":"Endothelin peptides and receptors in human kidney","volume":"91","author":"Karet","year":"1996","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.phrs.2013.12.003_bib0135","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/BF01647245","article-title":"Localization and quantification of [125i]-endothelin binding sites in human fetal and adult kidneys \u2013 relevance to renal ontogeny and pathophysiology","volume":"68","author":"Grone","year":"1990","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.phrs.2013.12.003_bib0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1679\/aohc.71.77","article-title":"Endothelin a receptor-like immunoreactivity on the basal infoldings of rat renal tubules and collecting ducts","volume":"71","author":"Yamamoto","year":"2008","journal-title":"Arch Histol Cytol"},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2013.12.003_bib0145","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1097\/00005344-199800001-00076","article-title":"Acute renal effects of endothelin-A blockade: interspecies differences","volume":"31","author":"Cernacek","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.003_bib0150","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1476-5381.1994.tb17070.x","article-title":"Characterization of receptors mediating vascular responses to endothelin-1 in the conscious rat","volume":"113","author":"Filep","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.003_bib0155","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/00004872-199009000-00004","article-title":"Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction","volume":"8","author":"Dahlof","year":"1990","journal-title":"J Hypertens"},{"key":"10.1016\/j.phrs.2013.12.003_bib0160","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1476-5381.2009.00267.x","article-title":"To scale or not to scale: the principles of dose extrapolation","volume":"157","author":"Sharma","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.003_bib0165","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrneph.2009.76","article-title":"Emerging therapies for chronic kidney disease: what is their role?","volume":"5","author":"Vilayur","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.phrs.2013.12.003_bib0170","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1751-7176.2012.00696.x","article-title":"Role of single-pill combination therapy in optimizing blood pressure control in high-risk hypertension patients and management of treatment-related adverse events","volume":"14","author":"Abdellatif","year":"2012","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.phrs.2013.12.003_bib0175","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1755-5922.2010.00260.x","article-title":"Blood pressure in renal disease: how to accomplish the goal?","volume":"30","author":"Robles","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.phrs.2013.12.003_bib0180","doi-asserted-by":"crossref","first-page":"F1448","DOI":"10.1152\/ajprenal.00340.2009","article-title":"Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes","volume":"297","author":"Gagliardini","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.phrs.2013.12.003_bib0185","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2013.12.003_bib0190","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(12)61272-0","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis","volume":"380","author":"Mahmoodi","year":"2012","journal-title":"Lancet"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661813002764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661813002764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T17:54:47Z","timestamp":1538934887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661813002764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":38,"alternative-id":["S1043661813002764"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2013.12.003","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2013.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}